Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Dysthymia: a review of pharmacological and behavioral factors

Molecular Psychiatry volume 5, pages 242–261 (2000)Cite this article

Abstract

Although dysthymia, a chronic, low-grade form of depression, has a morbidity rate as high as that of major depression, and increases the risk for major depressive disorder, limited information is available concerning the etiology of this illness. In the present report we review literature concerning the biological and characterological features of dysthymia, the effectiveness of antidepressant treatments, the influence of stressors in the precipitation and maintenance of the disorder, and both quality of life and psychosocial correlates of the illness. We also provisionally suggest that dysthymia may stem from disturbances of neuroendocrine and neurotransmitter functioning (eg, corticotropin releasing hormone and arginine vasopressin within the hypothalamus, or alternatively monoamine variations within several extrahypothalamic sites), and may also involve cytokine activation. The central disturbances may reflect phenotypic variations of neuroendocrine processes or sensitization of such mechanisms. It is suggested that chronic stressor experiences or stressors encountered early in life lead to the phenotypic neurochemical alterations, which then favor the development of the dysthymic state. Owing to the persistence of the neurochemical disturbances, vulnerability to double depression is increased, and in this instance treatment with antidepressants may attenuate the symptoms of major depression but not those of the basal dysthymic state. Moreover, the residual features of depression following treatment may be indicative of underlying neurochemical disturbances, and may also serve to increase the probability of illness recurrence or relapse.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Akiskal HS, Bolis CL, Cazzullo C, Costa e Silva JA, Gentil V, Lecrubier Y et al. Dysthymia in neurological disorders Mol Psychiatry 1996; 1: 478–491

    CAS  PubMed  Google Scholar 

  2. Howland RH, Thase ME . Biological studies of dysthymia Biol Psychiatry 1991; 30: 283–304

    Article  CAS  PubMed  Google Scholar 

  3. Klein DN, Kocsis JH, McCullough JP, Holzer CE, Hirschfeld RM, Keller MB . Symptomatology in dysthymic and major depressive disorder Psychiat Clin North Am 1996; 19: 41–53

    Article  CAS  Google Scholar 

  4. Ravindran AV, Merali Z, Anisman H . Dysthymia: a biological perspective. In: Licinio J, Bolis CL, Gold P (eds) Dysthymia: From Clinical Neuroscience to Treatment World Health Organization: Geneva 1997; pp21–44

    Google Scholar 

  5. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders Editions 3 and 4; 1980 1994

    Google Scholar 

  6. Akiskal HS . Dysthymic disorder: psychopathology of proposed chronic depressive subtypes Am J Psychiatry 1983; 140: 11–20

    Article  CAS  PubMed  Google Scholar 

  7. Freeman H . How the concept of dysthymia has developed.: a biological perspective. In: Licinio J, Bolis CL, Gold P (eds) Dysthymia: From Clinical Neuroscience to Treatment World Health Organization: Geneva 1997; pp1–8

    Google Scholar 

  8. World Health Organization . The ICD–10 classification of mental and behavioural disorders—clinical descriptions and diagnostic guidelines WHO: Geneva 1992

    Google Scholar 

  9. Akiskal HS . Towards a definition of dysthymia: boundaries with personality and mood disorders. In: Burton SW, Akiskal HS (eds) Dysthymic Disorders Gaskell: London 1990; pp1–12

    Google Scholar 

  10. McCullough JP, Kornstein SG, McCullough JP, Belyea-Caldwell S, Kaye AL, Roberts C et al. Differential diagnosis of chronic depressive disorders Psychiatr Clin North Am 1996; 19: 41–53

    Article  PubMed  Google Scholar 

  11. Keller MB, Sessa FM . Dysthymia: development and clinical course. In: Burton SW, Akiskal HS (eds) Dysthymic Disorders Gaskell: London 1990; pp13–23

    Google Scholar 

  12. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK . The de facto US mental and addictive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services Arch Gen Psychiatry 1993; 50: 85–94

    Article  CAS  PubMed  Google Scholar 

  13. Regier DA, Boyd JH, Burke JD, Rae DS, Myers JK, Kramer M et al. One-month prevalence of mental disorders in the United States Arch Gen Psychiatry 1988; 45: 977–986

    Article  CAS  PubMed  Google Scholar 

  14. Keller MB, Klein DN, Hirschfeld RMA, Docsis JH, McCullough JP, Miller I et al. Results of the DSM-IV Mood Disorders Field Trial Am J Psychiatry 1995; 152: 843–849

    Article  CAS  PubMed  Google Scholar 

  15. Kovacs M, Feinberg TL, Crouse-Novak MA, Paulauskas SL, Finkelstein R . Depressive disorders in childhood, I: a longitudinal prospective study of characteristics and recovery Arch Gen Psychiatry 1984; 41: 229–237

    Article  CAS  PubMed  Google Scholar 

  16. Shelton RC, Davidson J, Yonkers KA, Koran L, Thase ME, Pearlstein T et al. The undertreatment of dysthymia J Clin Psychiatry 1997; 58: 59–65

    Article  CAS  PubMed  Google Scholar 

  17. Howland RH . Pharmacotherapy of dysthymia: a review J Clin Psychopharmacol 1991; 11: 83–92

    Article  CAS  PubMed  Google Scholar 

  18. Versiani M . Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide J Affect Disord 1998; 51: 323–332

    Article  CAS  PubMed  Google Scholar 

  19. Akiskal HS, Weise RE . The clinical spectrum of so-called ‘minor’ depressions Am J Psychother 1992; 46: 9–22

    Article  CAS  PubMed  Google Scholar 

  20. Markowitz JC . Psychotherapy of dysthymia Am J Psychiatry 1994; 151: 1114–1121

    Article  CAS  PubMed  Google Scholar 

  21. McCullogh JP . Psychotherapy for dysthymia: a naturalistic study of ten patients J Nerv Ment Dis 1991; 179: 734–740

    Article  Google Scholar 

  22. Ravindran AV, Anisman H, Merali Z, Charbonneau Y, Telner J, Bialik RJ et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments Am J Psychiatry 1999; 156: 1608–1617

    Article  CAS  PubMed  Google Scholar 

  23. Dunner DL, Schmaling KB, Hendrickson H, Becker J, Lehman A, Bea C . Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder Depression 1996; 4: 34–41

    Article  CAS  PubMed  Google Scholar 

  24. Keller MB, Shapiro RW . Double depression: superimposition of acute depressive episodes on chronic depressive disorders Am J Psychiatry 1982; 139: 438–442

    Article  CAS  PubMed  Google Scholar 

  25. Keller MB, Lavori PW, Endicott J, Coryell W, Klerman GL . Double depression: two year follow up Am J Psychiatry 1983; 140: 689–694

    Article  CAS  PubMed  Google Scholar 

  26. Weissman MM, Leaf PJ, Bruce ML, Florio L . The epidemiology of dysthymia in five communities: rates, risks, comorbidity and treatment Am J Psychiatry 1988; 145: 815–819

    Article  CAS  PubMed  Google Scholar 

  27. Levitt AJ, Joffe RT, Sokolov STH . Does the chronological relationship between the onset of dysthymia and major depression influence subsequent response to antidepressants? J Affect Disord 1998; 47: 169–175

    Article  CAS  PubMed  Google Scholar 

  28. Pini S, Cassano GB, Simonini E, Savino M, Russo A, Montgomery SA . Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia J Affect Disord 1997; 42: 145–153

    Article  CAS  PubMed  Google Scholar 

  29. Coryell W, Endicott J, Andreasen N, Keller MB, Clayton PJ, Hirschfeld RM et al. Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data Am J Psychiatry 1988; 145: 293–300

    Article  CAS  PubMed  Google Scholar 

  30. Gaynes BN, Magruder KM, Burns BJ, Wagner R, Yarnall KSH, Broadhead WE . Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression? Gen Hosp Psychiatry 1999; 21: 158–167

    Article  CAS  PubMed  Google Scholar 

  31. Pepper CM, Klein DN, Anderson RL, Riso LP, Ouimette P, Lizardi H . DSM-III-R axis II comorbidity in dysthymia and major depression Am J Psychiatry 1995; 152: 239–247

    Article  CAS  PubMed  Google Scholar 

  32. Markowitz JC, Moran MM, Kocsis JH, Frances AJ . Prevalence and comorbidity of dysthymic disorder among psychiatric outpatients J Affect Disord 1992; 24: 63–67

    Article  CAS  PubMed  Google Scholar 

  33. Marin DB, Kocsis JH, Frances AJ, Klerman GL . Personality disorders in dysthymia J Personality Disord 1993; 7: 223–231

    Article  Google Scholar 

  34. Anderson RL, Klein DN, Riso LP, Ouimette PC, Lizardi H, Schwartz JE . The subaffective-character spectrum subtyping distinction primary early-onset dysthymia: a clinical and familial study J Affect Disord 1996; 38: 13–22

    Article  CAS  PubMed  Google Scholar 

  35. Garyfallos G, Adamopoulou A, Karastergiou A, Voikli M, Sotiropoulou A, Donias S et al. Personality disorders in dysthymia and major depression Acta Psychiat Scand 1999; 99: 332–340

    Article  CAS  PubMed  Google Scholar 

  36. Klein DN, Schatzberg AF, McCullough JP, Keller MB, Dowling F, Goodman D et al. Early- versus late-onset dysthymic disorder: comparison in out-patients with superimposed major depressive episodes J Affect Disord 1999; 52: 187–196

    Article  CAS  PubMed  Google Scholar 

  37. Klein DN, Shih JH . Depressive personality: associations with DSM-III-R mood and personality disorders and negative and positive affectivity, 30-month stability, and prediction of course of Axis I depressive disorders J Abn Psychol 1998; 107: 319–327

    Article  CAS  Google Scholar 

  38. Davidson KM, Ritson FB . The relationship between alcohol dependence and depression Alcohol Alcohol 1993; 28: 147–155

    CAS  PubMed  Google Scholar 

  39. Lynskey MT . The comorbidity of alcohol dependence and affective disorders: treatment implications Drug Alcohol Depend 1998; 52: 201–209

    Article  CAS  PubMed  Google Scholar 

  40. Eames SL, Westermeyer J, Crosby RD . Substance use and abuse among patients with comorbid dysthymia and substance disorder Am J Drug Alcohol Abuse 1998; 24: 541–550

    Article  CAS  PubMed  Google Scholar 

  41. Westermeyer J, Eames SL, Nugent S . Comorbid dysthymia and substance disorder: treatment history and cost Am J Psychiatry 1998; 155: 1556–1560

    Article  CAS  PubMed  Google Scholar 

  42. Miller IW, Norman WH, Dow MG . Psychosocial characteristics of ‘double depression’ Am J Psychiatry 1986; 143: 1042–1044

    Article  CAS  PubMed  Google Scholar 

  43. Akiskal HS, King D, Rosenthal TL, Robinson S, Scott-Strauss A . Chronic depressions, 1: clinical and familial characteristics in 137 probands J Affect Disord 1981; 3: 297–315

    Article  CAS  PubMed  Google Scholar 

  44. Anisman H, Zalcman S, Zacharko RM . The impact of stressors on immune and central transmitter activity: bidirectional communication Rev Neurosci 1993; 4: 147–180

    Article  CAS  PubMed  Google Scholar 

  45. Hirschfeld RMA . Personality and dysthymia. In: Burton SW,Akiskal HS (eds) Dysthymic Disorders Gaskell: London 1990; pp69–77

    Google Scholar 

  46. Klein DN, Taylor EB, Dickstein S, Harding K . The early-late onset distinction in DSM-III-R dysthymia J Affect Disord 1988; 14: 25–33

    Article  CAS  PubMed  Google Scholar 

  47. Kocsis JH, Frances AJ . A critical discussion of DSM-III dysthymic disorder Am J Psychiatry 1987; 144: 1534–1542

    Article  CAS  PubMed  Google Scholar 

  48. McCullough JP, Braith, JA, Chapman RC, Kasnetz MD, Carr KF, Cones JH et al. Comparison of early and late onset dysthymia J Nerv Ment Dis 1990; 178: 577–581

    Article  CAS  PubMed  Google Scholar 

  49. Sansone RA, Wiederman MW, Sansone LA, Touchet B . Early-onset dysthymia and personality disturbance among patients in a primary care setting J Nerv Ment Dis 1998; 186: 57–58

    Article  CAS  PubMed  Google Scholar 

  50. Klein DN, Taylor EB, Dickstein S, Harding K . Primary early-onset dysthymia: comparison with primary non-bipolar non-chronic major depression on demographic, clinical, familial, personality, and socioenvironmental characteristics and short-term outcome J Abn Psychol 1988; 97: 387–398

    Article  CAS  Google Scholar 

  51. Brunello N, Akiskal H, Boyer P, Gessa GL, Howland RH, Langer SZ et al. Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas J Affect Disord 1999; 52: 275–290

    Article  CAS  PubMed  Google Scholar 

  52. Walker E, Katon W, Jemelka R . Psychiatric disorders and medical care utilization among people who report fatigue in the general population J Gen Intern Med 1993; 8: 436–440

    Article  CAS  PubMed  Google Scholar 

  53. Epstein SA, Kay G, Clauw D, Heaton R, Klein D, Krupp L et al. Psychiatric disorders in patients with fibromyalgia: a multicentre investigation Psychosomatics 1999; 40: 57–63

    Article  CAS  PubMed  Google Scholar 

  54. Keel P . Psychological and psychiatric aspects of fibromyalgia syndrome (FMS) Z Rheumatol 1998; 57: 97–100

    Article  PubMed  Google Scholar 

  55. Anisman H, Ravindran AV, Griffiths J, Merali Z . Behavioral, endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features Mol Psychiatry 1999; 4: 182–188

    Article  CAS  PubMed  Google Scholar 

  56. Cannon JG, Angel JB, Abad LW, Vannier E, Mileno MD, Fagioli L et al. Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 type II secretion in chronic fatigue syndrome J Clin Immunol 1997; 17: 253–261

    Article  CAS  PubMed  Google Scholar 

  57. Chao CC, Janoff EN, Hu SX, Thomas K, Gallagher M, Tsang M et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome Cytokine 1991; 3: 292–298

    Article  CAS  PubMed  Google Scholar 

  58. Mitsikostas DD, Thomas AM . Comorbidity of headache and depressive disorders Cephalalgia 1999; 19: 211–217

    Article  CAS  PubMed  Google Scholar 

  59. Okasha A, Ismail MK, Khalil AH, EI Fiki R, Soliman A, Okasha T . A psychiatric study of nonorganic chronic headache patients Psychosomatics 1999; 40: 233–238

    Article  CAS  PubMed  Google Scholar 

  60. Puca F, Genco S, Prudenzano MP, Savarese M, Bussone G, D’ Amico D et al. Psychiatric comorbidity and psychosocial stress in patients with tension-type headache from headache centers in Italy Cephalalgia 1999; 19: 159–164

    Article  CAS  PubMed  Google Scholar 

  61. Poewe W, Luginger E . Depression in Parkinson's disease: impediments to recognition and treatment options Neurology 1999; 52: S2–S6

    Article  CAS  PubMed  Google Scholar 

  62. Taylor CA, Jung HY . Disorders of mood after traumatic brain injury Sem Clin Neuropsychiat 1998; 3: 224–231

    CAS  Google Scholar 

  63. Rothwell NJ . Cytokines—killers in the brain J Physiol 1999; 514: 3–17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Schildkraut JJ . Current status of the catecholamine hypothesis of affective disorders. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: A Generation of Progress Raven Press: New York 1978; pp1223–1234

    Google Scholar 

  65. Coppen A, Prange AJ Jr, Whybrow PC, Noguera R . Abnormalities of indolamines in affective disorders Arch Gen Psychiatry 1972; 26: 474–478

    Article  CAS  PubMed  Google Scholar 

  66. van Praag HM . Amine hypotheses of affective disorders. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of Psychopharmacology Plenum: New York 1978; pp187–298

    Chapter  Google Scholar 

  67. Brown AS, Gershon S . Dopamine and depression J Neurotrans 1993; 91: 75–109

    CAS  Google Scholar 

  68. Jimerson DC . Role of dopamine mechanisms in the affective disorders. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress Raven: New York 1987; pp505–511

    Google Scholar 

  69. Siever LJ . Role of noradrenergic mechanisms in the etiology of the affective disorders. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress Raven: New York 1987; pp493–504

    Google Scholar 

  70. Antelman SM, Chiodo LA . Amphetamine as a stressor. In: Creese I (ed) Stimulants: Neurochemical, Behavioral and Clinical Perspectives Raven Press: New York 1983; pp269–300

    Google Scholar 

  71. Meltzer HY, Lowy MT . The serotonin hypothesis of depression. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress Raven Press: New York 1987; pp513–526

    Google Scholar 

  72. Sulser F . Antidepressant treatments and regulation of norepinephrine-receptor-coupled adenylate cyclase systems in brain. In: Usdin E, Asberg M, Bertilsson L, Sjoqvist F (eds) Frontiers in Biochemical and Pharmacological Research in Depression Raven: New York 1984; pp249–262

    Google Scholar 

  73. Maas JW . Biogenic amines and depression Arch Gen Psychiatry 1975; 32: 1357–1361

    Article  CAS  PubMed  Google Scholar 

  74. Checkley SA . Neuroendocrine mechanisms and the precipitation of depression by life events Br J Psychiatry 1992; 160: 7–17

    Article  Google Scholar 

  75. Joffe RT, Bagby RM, Levit AJ . The thyroid and melancholia Psychiatr Res 1992; 42: 73–80

    Article  CAS  Google Scholar 

  76. Prange AJ, Loosen PT, Wilson IC, Lipton MA . The therapeutic use of hormones of the thyroid axis in depression. In: Post RM, Ballenger JC (eds) Neurobiology of Mood Disorders Williams & Wilkins: Baltimore 1984; pp311–322

    Google Scholar 

  77. Rubin RT, Poland RE . The dexamethasone suppression test in depression: advantages and limitation. In: Burrows GD, Norman TR, McGuire KP (eds) Biological Psychiatry: Recent Studies Libbey: London 1984; pp76–83

    Google Scholar 

  78. Brown GW, Harris TO . Life Events and Illness Guilford Press: New York 1989

    Google Scholar 

  79. Brown GW, Harris TO . Social Origins of Depression: A Study of Psychiatric Disorder in Women Free Press: New York 1978

    Google Scholar 

  80. Robins CJ, Block P . Personal vulnerability, life events, and depressive symptoms: a test of a specific interactional model J Pers Soc Psychol 1988; 54: 847–852

    Article  CAS  PubMed  Google Scholar 

  81. Abramson LY, Seligman MEP, Teasdale JD . Learned helplessness in humans: critique and reformulation J Abn Psychol 1978; 87: 49–74

    Article  CAS  Google Scholar 

  82. Alloy LB, Clements CM . Illusion of control: invulnerability to negative affect and depressive symptoms after laboratory and natural stressors J Abn Psychol 1992; 2: 234–245

    Article  Google Scholar 

  83. Anisman H, Zalcman S, Shanks N, Zacharko RM . Multisystem regulation of performance deficits induced by stressors: an animal model of depression. In: Boulton A, Baker G, Martin-Iverson M (eds) Neuromethods, vol. 19: Animal Models of Psychiatry, II Humana Press: New Jersey 1991; pp1–59

    Google Scholar 

  84. Weiss JM, Simson PE . Electrophysiology of the locus coeruleus: implications for stress-induced depression. In: Koob GF, Ehlers CL, Kupfer DJ (eds) Animal Models of Depression Birkhauser: Boston 1989; pp111–134

    Chapter  Google Scholar 

  85. Heinsbroek R, van Haaren F, Feenstra M, van de Poll N . Changes in dopamine and noradrenaline activity in the frontal cortex produced by controllable and uncontrollable shock Behav Pharmacol 1989; 1: 61

    Google Scholar 

  86. Petty F, Sherman A . A neurochemical differentiation between exposure to stress and the development of learned helplessness Drug Devel Res 1982; 2: 43–45

    Article  Google Scholar 

  87. Ritter S, Pelzer NL . Magnitude of stress induced norepinephrine depletion varies with age Brain Res 1978; 152: 1701–1705

    Article  Google Scholar 

  88. Tanaka M, Kohno Y, Nakagawa R et al. Time related differences in noradrenaline turnover in rat brain regions by stress Pharm Biochem Behav 1982; 16: 315–319

    Article  CAS  Google Scholar 

  89. Anisman H, Sklar LS . Catecholamine depletion upon reexposure to stress: mediation of the escape deficits produced by inescapable shock J Comp Physiol Psychol 1979; 93: 610–625

    Article  CAS  PubMed  Google Scholar 

  90. Cassens G, Roffman M, Kuruc A, Orsulak PJ, Schildkraut JJ . Alterations of brain norepinephrine metabolism induced by environmental stimuli paired with inescapable shock Science 1980; 209: 1138–1140

    Article  CAS  PubMed  Google Scholar 

  91. Doherty MD, Gratton A . High-speed chronoamperometric measurements of mesolimbic and nigostriatal dopamine release associated with repeated daily stress Brain Res 1992; 586: 295–302

    Article  CAS  PubMed  Google Scholar 

  92. Herman JP, Guillonneau D, Dantzer R, Scatton B, Semerdjian-Rouquier L, LeMoal M . Differential effects of inescapable footshock and stimuli previously paired with inescapable footshocks on dopamine turnover in cortical and limbic areas of the rat Life Sci 1982; 30: 2207–2214

    Article  CAS  PubMed  Google Scholar 

  93. Roth RH, Tam S-Y, Ida Y, Yang J-X, Deutch Y . Stress and mesocorticolimbic dopamine system Ann NY Acad Sci 1988; 537: 138–147

    Article  CAS  PubMed  Google Scholar 

  94. Antelman SM . Time-dependent sensitization as the cornerstone for a new approach to pharmacotherapy: drugs as foreign/stressful stimuli Drug Dev Res 1988; 14: 1–30

    Article  CAS  Google Scholar 

  95. Nisenbaum LK, Abercrombie ED . Enhanced tyrosine hydroxylation in hippocampus of chronically stressed rats upon exposure to a novel stressor J Neurochem 1992; 58: 276–281

    Article  CAS  PubMed  Google Scholar 

  96. Nisenbaum LK, Zigmond MJ, Sved AF, Abercrombie ED . Prior exposure to chronic stress results in enhanced synthesis and release of hippocampal norepinephrine in response to a novel stressor J Neurosci 1991; 11: 1478–1484

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Deutch AY, Roth RH . The determinants of stress-induced activation of the prefrontal cortical dopamine system Prog Brain Res 1990; 85: 367–402

    Article  CAS  PubMed  Google Scholar 

  98. Herman JP, Stinus L, Le Moal M . Repeated stress increases locomotor response to amphetamine Psychopharmacology 1984; 84: 431–435

    Article  CAS  PubMed  Google Scholar 

  99. Irwin M . Psychoneuroimmunology of depression. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress Raven Press: New York 1995; pp983–998

    Google Scholar 

  100. Kvetnansky R . Recent progress in catecholamines under stress. In: Usdin E, Kvetnansky R, Kopin IJ (eds) Catecholamines and Stress: Recent Advances Elsevier: New York 1980; pp7–20

    Google Scholar 

  101. Zacharko RM, Anisman H . Pharmacological, biochemical and behavioral analyses of depression: animal models. In: Koob GF, Ehlers CL, Kupfer DJ (eds) Animal Models of Depression Birkhauser: Boston 1989; 204–238

    Chapter  Google Scholar 

  102. Stone EA . Central cyclic-AMP-linked noradrenergic receptors: new findings on properties as related to the actions of stress Neurosci Biobehav Rev 1987; 11: 391–398

    Article  CAS  PubMed  Google Scholar 

  103. Molina VA, Volosin M, Cancela L, Keller E, Murua VS, Basso AM . Effect of chronic variable stress on monoamine receptors: influence of imipramine administration Pharmacol Biochem Behav 1990; 35: 335–340

    Article  CAS  PubMed  Google Scholar 

  104. Willner P . The anatomy of melancholy: the catecholamine hypothesis of depression revisted Rev Neurosci 1987; 1: 77–99

    CAS  Google Scholar 

  105. Anisman H, Merali Z . Chronic stressors and animal models of depression: distinguishing characteristics and individual profiles Psychopharmacology 1997; 134: 330–332

    Article  CAS  PubMed  Google Scholar 

  106. Schulkin J, Gold PW, McEwen BS . Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load Psychoneuroendocrinology 1998; 23: 219–243

    Article  CAS  PubMed  Google Scholar 

  107. Holsboer F . Neuroendocrinology of mood disorders. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress Raven Press: New York 1995; pp957–969

    Google Scholar 

  108. Maes M, Meltzer HY . The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress Raven Press: New York 1995; pp933–944

    Google Scholar 

  109. Plotsky PM, Owens MJ, Nemeroff CB . Neuropeptide alterations in mood disorders. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress Raven Press: New York 1995; pp971–981

    Google Scholar 

  110. Schatzberg AF, Schildkraut JJ . Recent studies on norepinephrine systems on mood disorders. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress Raven: New York 1995; pp911–920

    Google Scholar 

  111. Ravindran AV, Bialik RJ, Lapierre YD . Primary early onset dysthymia, biochemical correlates of the therapeutic response to fluoxetine: 1. Platelet monoamine oxidase and the dexamethasone suppression test J Affect Disord 1994; 31: 111–117

    Article  CAS  PubMed  Google Scholar 

  112. Jansen LMC, Gispen-de Wied CC, Jansen MA, van der Gaag RJ, Matthys W, van Engeland H . Pituitary-adrenal reactivity in a child psychiatric population: salivary cortisol response to stressors Eur Psychopharmacol 1999; 9: 67–75

    CAS  Google Scholar 

  113. Szadoczky E, Sazekas I, Rihmer Z, Arato M . The role of psychosocial and biological variables in separating chronic and non-chronic major depression and early-late onset dysthymia J Affect Disord 1994; 32: 1–11

    Article  CAS  PubMed  Google Scholar 

  114. Versiani M, Amrein R, Stabl M, the International Collaborative Study Group . Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial Int Clin Psychopharm 1997; 12: 183–193

    Article  CAS  Google Scholar 

  115. Lechin F, van der Dijs B, Orozco B, Lechin AE . Plasma neurotransmitters, blood pressure, and heart rate during supine resting, orthostasis, and moderate exercise in dysthymic depressed patients Biol Psychiatry 1994; 37: 884–891

    Article  Google Scholar 

  116. Wahlund B, Saaf J, Wetterberg L . Clinical symptoms and platelet monoamine oxidase in subgroups and different states of affective disorders J Affect Disord 1995; 35: 75–87

    Article  CAS  PubMed  Google Scholar 

  117. Ravindran AV, Bialik RJ, Brown GM, Lapierre YD . Primary early onset dysthymia, biochemical correlates of the therapeutic response to fluoxetine: II. Urinary metabolites of serotonin, norepinephrine, epinephrine and melatonin J Affect Disord 1994; 31: 119–123

    Article  CAS  PubMed  Google Scholar 

  118. Yee CM, Miller GA . A dual-task analysis of resource allocation in dysthymia and anhedonia J Abn Psychol 1994; 103: 625–636

    Article  CAS  Google Scholar 

  119. Yee CM, Deldin PJ, Miller GA . Early stimulus processing in dysthymia and anhedonia J Abn Psychol 1992; 101: 230–233

    Article  CAS  Google Scholar 

  120. Akiskal HS, Lemmi H, Dickson H, King D, Yerevanian B, Van Valkenberg C . Chronic depressions. Part 2. Sleep EEG differentiation of primary dysthymic disorders from anxious depressions J Affect Disord 1984; 6: 287–295

    Article  CAS  PubMed  Google Scholar 

  121. Akiskal HS, Rosenthal TL, Haykal RF, Lemmi H, Rosenthal RT, Scott-Strauss A . Characterological depressions: clinical and sleep EEG findings separating ‘subaffective dysthymias’ from ‘character spectrum’ disorders Arch Gen Psychiatry 1980; 37: 777–783

    Article  CAS  PubMed  Google Scholar 

  122. Akiskal HS, Judd LL, Gillin C, Lemmi H . Subthreshold depressions: clinical and polysomnographic validation of dysthymic, residual and masked forms J Affect Disord 1997; 45: 53–63

    Article  CAS  PubMed  Google Scholar 

  123. Arriaga F, Cavaglia F, Matospires A, Lara E, Paiva T . EEG sleep characteristics in dysthymia and major depressive disorder Neuropsychobiology 1995; 32: 128–131

    Article  CAS  PubMed  Google Scholar 

  124. Baldwin D, Rudge S, Thomas S . Dysthymia: options in pharmacotherapy CNS Drugs 1995; 4: 422–431

    Article  CAS  Google Scholar 

  125. Conte HR, Karasu TB . A review of treatment studies of minor depression: 1980–1991 Am J Psychiatry 1992; 46: 58–74

    CAS  Google Scholar 

  126. Dunner DL . Treatment of dysthymic disorder Depress Anxiety 1998; 8: 54–58

    Article  PubMed  Google Scholar 

  127. Frank E, Thase ME . Natural history and preventative treatment of recurrent mood disorders Ann Rev Med 1999; 50: 453–468

    Article  CAS  PubMed  Google Scholar 

  128. Gorman JM, Kent JM . SSRIs and SNRIs: broad spectrum of efficacy beyond major depression J Clin Psychiatry 1999; 60: 33–38

    Article  PubMed  Google Scholar 

  129. Lopez Ibor JJ, Frances A, Jones C . Dysthymic disorder: a comparison of DSM-IV and ICD-10 and issues in differential diagnosis Acta Psychiatr Scand 1994; 89: (suppl 383) 12–18

    Article  Google Scholar 

  130. Stewart JW, McGrath PJ, Liebowitz MR . Treatment outcome validation of DSM-III depressive subtypes: clinical usefulness in outpatients with mild to moderate depression Arch Gen Psychiatry 1985; 42: 1148–1153

    Article  CAS  PubMed  Google Scholar 

  131. Friedman RA, Markowitz JC, Parides M, Kocsis JH . Acute response of social functioning in dysthymic patients with desipramine J Affect Disord 1995; 34: 85–88

    Article  CAS  PubMed  Google Scholar 

  132. Keller MB, Gelengerg AJ, Hirschfeld RN, Rush AJ, Thase ME, Kocsis JH et al. The treatment of chronic depression, part 2: a double blind, randomized trial of sertraline and imipramine J Clin Psychiatry 1998; 59: 598–607

    Article  CAS  PubMed  Google Scholar 

  133. Kocsis JH, Frances AJ, Voss C, Mann JJ, Mason BJ, Sweeney J . Imipramine treatment for chronic depression Arch Gen Psychiatry 1988; 45: 253–257

    Article  CAS  PubMed  Google Scholar 

  134. Kocsis JH, Thase M, Koran L, Halbreich U, Yonkers K . Pharmacotherapy of pure dysthymia: sertraline vs imipramine and placebo Eur Neuropsychopharm 1994; 4: (suppl 3) S204

    Article  Google Scholar 

  135. Marin DB, Kocsis JH, Frances AJ, Parides M . Desipramine for the treatment of ‘pure’ dysthymia versus ‘double’ depression Am J Psychiatry 1994; 151: 1079–1080

    Article  CAS  PubMed  Google Scholar 

  136. Stewart JW, McGrath PJ, Quitkin FM, Rabkin J, Harrison W, Wager S et al. Chronic depression: response to placebo, imipramine, and phenelzine J Clin Psychopharmacol 1993; 13: 391–396

    CAS  PubMed  Google Scholar 

  137. Versiani M, Nardi D, Capponi R, Costa DA, Magistris H, Ucha Udabe R . Moclobemide compared with imipramine in the treatment of chronic depression (dysthymia DSM-III-R): a double-blind placebo-controlled trial Clin Neuropharmacol 1992; 15: (suppl 1) 148b

    Google Scholar 

  138. Petursson H . Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia Acta Psychiatr Scand 1995; 91: (suppl 386) 36–39

    Article  Google Scholar 

  139. Vallejo J, Gasto C, Catalan R, Salamero M . Double blind study of imipramine versus phenelzine in melancholias and dysthymic disorders Br J Psychiatry 1987; 151: 639–642

    Article  CAS  PubMed  Google Scholar 

  140. Baumhackl U, Biziere K, Fischbach R, Geretsegger C, Hebenstreit G, Radmayr E et al. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind multicentre study Br J Psychiatry 1989; suppl 6: 78–83

  141. Botte L, Evrard JL, Gilles C, Stenier P, Wolfrum C . Controlled comparison of RO 11–1163 (mocobemide) and placebo I the treatment of depression Acta Psychiat Belg 1992; 92: 355–369

    CAS  Google Scholar 

  142. Duarte A, Camozzi CR . Moclobemide versus fluoxetine in the treatment of dysthmia 9th World Congress of Psychiatry abstract, Rio de Janeiro 1993

    Google Scholar 

  143. Versiani M . Pharmacotherapy of dysthymia: a controlled study with imipramine, moclobemide or placebo Neuropsychopharmacology 1993; 10: (3S) 298

    Google Scholar 

  144. Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Dasch K et al. A randomized double blind study of fluoxetine versus placebo in the treatment of dysthymia Am J Psychiatry 1993; 150: 1169–1175

    Article  CAS  PubMed  Google Scholar 

  145. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia Arch Gen Psychiatry 1996; 53: 777–784

    Article  CAS  PubMed  Google Scholar 

  146. Vanelle JM, Attar-Levy D, Poirier MF, Bouhassira M, Blin P, Olie JP . Controlled efficacy study of fluoxetine in dysthymia Br J Psychiatry 1997; 170: 345–350

    Article  CAS  PubMed  Google Scholar 

  147. Bakish D, Lapierre YD, Weinstein R, Klein J, Wiens A, Jones B et al. Ritanserin, imipramine and placebo in the treatment of dysthymic disorder J Clin Psychopharmacol 1993; 13: 409–414

    Article  CAS  PubMed  Google Scholar 

  148. Bersani G, Pozzi F, Marini S, Grispini A, Pasini A, Ciani N . 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin Acta Psychiatr Scand 1991; 83: 244–248

    Article  CAS  PubMed  Google Scholar 

  149. Burrows GD, Maguire KP, Norman TR . Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review J Clin Psychiatry 1998; 59: 4–7

    CAS  PubMed  Google Scholar 

  150. Dunner DL, Hendrickson HE, Bea C, Budech CB . Venlafaxine in dysthymic disorder J Clin Psychiat 1997; 58: 528–531

    Article  CAS  Google Scholar 

  151. Ravindran AV, Charbonneau Y, Zaharia M, Al-Zaid K, Wiens A, Anisman H . Efficacy and tolerability of venlafaxine in the treatment of primary dysthymia J Psychiat Neurosci 1998; 23: 288–292

    CAS  Google Scholar 

  152. Harrison W, Rabkin J, Stewart JW, McGrath PJ, Tricamo E, Quitkin F . Phenelzine for chronic depressions: a study of continuation treatment J Clin Psychiatry 1986; 47: 346–349

    CAS  PubMed  Google Scholar 

  153. Tyrer P, Seivewright N, Murphy S, Ferguson B, Kingdon D, Barczak P et al. The Nottingham study of neurotic disorder: comparison of drug and psychological treatments Lancet 1988; 8605: 235–240

    Article  Google Scholar 

  154. Stewart JW, McGrath PJ, Quitkin FM, Harrison W, Markowitz J, Wager S et al. Relevance of DSM-III depressive subtype and chronicity to antidepressant efficacy in atypical depression: differential response to phenelzine, imipramine, and placebo Arch Gen Psychiatry 1989; 46: 1080–1087

    Article  CAS  PubMed  Google Scholar 

  155. Costa-e-Silva JA . Treatment of dysthymic disorder with low-dose amisulpride. A comparative study of 50mg/day amisulpride versus placebo Ann Psychiatry 1990; 5: 242–249

    Google Scholar 

  156. Lecrubier Y, Boyer P, Turjanski S, Rein W, the Amisulpride Study Group . Amisulpride versus imipramine and placebo in dysthymia and major depression J Affect Disord 1997; 43: 95–103

    Article  CAS  PubMed  Google Scholar 

  157. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O . Amisulpride versus amineptine and placebo for the treatment of dysthymia Neuropsychobiology 1999; 39: 25–32

    Article  CAS  PubMed  Google Scholar 

  158. Ravindran AV, Bialik RJ, Lapierre YD . Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia Can J Psychiatry 1994; 39: 21–26

    Article  CAS  PubMed  Google Scholar 

  159. Friedman RA, Parides M, Baff R, Moran M, Kocsis JH . Predictors of response to desipramine in dysthymia J Clin Psychopharm 1995; 15: 280–283

    Article  CAS  Google Scholar 

  160. Kocsis JH, Friedman RA, Markowitz JC, Leon AC, Miller NL, Gniwesch L et al. Maintenance therapy for chronic depression. A controlled clinical trial of desipramine Arch Gen Psychiatry 1996; 53: 769–774

    Article  CAS  PubMed  Google Scholar 

  161. Santagostino G, Cucchi ML, Frattini P, Zerbi F, Di Paolo E, Preda S et al. The influence of alprazolam on the monoaminergic neurotransmitter systems in dysthymic patients. Relationship to clinical response Pharmacopsychiatry 1998; 31: 131–136

    Article  CAS  PubMed  Google Scholar 

  162. Smeraldi E . Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study J Affect Disord 1998; 48: 47–56

    Article  CAS  PubMed  Google Scholar 

  163. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR . Dehydroepiandrosterone treatment of midlife dysthymia Biol Psychiatry 1999; 45: 1533–1541

    Article  CAS  PubMed  Google Scholar 

  164. Rudas S, Schmitz M, Pichler P, Baumgartner A . Treatment of refractory chronic depression and dysthymia with high-dose thyroxin Biol Psychiatry 1999; 45: 229–233

    Article  CAS  PubMed  Google Scholar 

  165. McCleod MN, Gaynes BN, Golden RN . Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients J Clin Psychiatry 1999; 60: 237–240

    Article  Google Scholar 

  166. Kocsis JH, Sutton BM, Frances AJ . Long-term follow-up of chronic depression treated with imipramine J Clin Psychiatry 1991; 52: 56–59

    CAS  PubMed  Google Scholar 

  167. Hellerstein DJ, Samstag LW, Cantillon M, Maurer M, Rosenthal J, Yanowitch P et al. Follow-up assessment of medication-treated dysthymia Prog Neuro-Psychopharmacol Biol Psychiatry 1996; 20: 427–442

    Article  CAS  Google Scholar 

  168. Wise RA . The anhedonia hypothesis: mark III Behav Brain Sci 1985; 8: 178–186

    Article  Google Scholar 

  169. Fibiger HC . Neurobiology of depression: focus on dopamine. In: Gessa GL, Fratta W, Pani L, Serra G (eds) Depression and Mania: From Neurobiology to Treatment Lippincott-Raven: Philadelphia 1995; pp1–42

    Google Scholar 

  170. Kapur S, Mann JJ . Role of the dopaminergic system in depression Biol Psychiatry 1992; 32: 1–17

    Article  CAS  PubMed  Google Scholar 

  171. Maier W, Benkert O . Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies Psychopharmacology 1994; 115: 495–501

    Article  CAS  PubMed  Google Scholar 

  172. Leon CA, Vigoya J, Conde S, Campo G, Castrillon E, Leon A . Comparison of the effect of amisulpride and viloxazine in the treatment of dysthymia Acta Psiquiatr Psicol Am Lat 1994; 40: 41–49

    CAS  PubMed  Google Scholar 

  173. Goldstein RB, Weissman MM, Adams PB, Horwath E, Lish JD, Charney D et al. Psychiatric disorders in relatives of probands with panic disorder and/or major depression Arch Gen Psychiatry 1994; 51: 383–394

    Article  CAS  PubMed  Google Scholar 

  174. Goodman DW, Barnhill J . Family and genetic epidemiologic studies. In: Kocsis JH, Klein DN (eds) Diagnosis and Treatment of Chronic Depression Guilford Press: New York 1995; pp103–123

    Google Scholar 

  175. Klein DN, Riso LP, Donaldson SK, Schwartz JE, Anderson RL, Ouimette PL et al. Family study of early-onset dysthymia. Mood and personality disorders in relatives of outpatients with dysthymia and episodic major depression and normal controls Arch Gen Psychiatry 1995; 52: 487–496

    Article  CAS  PubMed  Google Scholar 

  176. Donaldson SK, Klein DN, Riso LP, Schwartz JE . Comorbidity between dysthymic and major depressive disorders: a family study analysis J Affect Disord 1997; 42: 103–111

    Article  CAS  PubMed  Google Scholar 

  177. Klein DN, Riso LP, Anderson RL . DSM-III-R dysthymia: antecedents and underlying assumptions. In: Chapman LJ, Chapman JP, Fowles DC (eds) Progress in Experimental Personality and Psychopathology Research Vol 16. Springer: New York: 1993; pp222–253

    Google Scholar 

  178. Riso LP, Klein DN, Ferro T, Kasch KL, Pepper CM, Schwartz JE et al. Understanding the comorbidity between early-onset dysthymia and cluster B personality disorders: a family study Am J Psychiatry 1996; 153: 900–906

    Article  CAS  PubMed  Google Scholar 

  179. Ohara K, Nagai M, Suzuki Y, Ohara K . Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression NeuroReport 1998; 9: 1305–1308

    Article  CAS  PubMed  Google Scholar 

  180. Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, Meyer JM et al. A registry-based twin study of depression in men Arch Gen Psychiatry 1998; 55: 468–472

    Article  CAS  PubMed  Google Scholar 

  181. Monroe SM, Depue RA . Life stress and depression. In: Becker J, Kleinman A (eds) Psychosocial Aspects of Depression Erlbaum: Hillsdale 1991; pp101–130

    Google Scholar 

  182. Monroe SM, Simons AD . Diathesis-stress theories in the context of life stress research: implications for the depressive disorders Psychol Bull 1991; 110: 406–425

    Article  CAS  PubMed  Google Scholar 

  183. Finlay-Jones R, Brown GW . Types of stressful life events and the onset of anxiety and depressive disorders Psychol Med 1981; 11: 803–816

    Article  CAS  PubMed  Google Scholar 

  184. Lazarus RS . Coping theory and research: past, present, and future Psychosom Med 1993; 55: 234–247

    Article  CAS  PubMed  Google Scholar 

  185. Hammen C . Generation of stress in the course of unipolar depression J Abn Psychol 1991; 100: 555–561

    Article  CAS  Google Scholar 

  186. Overholser JC . Emotional reliance and social loss: effects on depressive symptomatology J Pers Assess 1990; 55: 618–629

    Article  CAS  PubMed  Google Scholar 

  187. Ravindran AV, Griffiths J, Merali Z, Anisman H . Primary dysthymia: a study of several psychosocial, endocrine and immunecorrelates J Affect Disord 1996; 40: 73–84

    Article  CAS  PubMed  Google Scholar 

  188. Ravindran A, Griffiths J, Waddell C, Anisman H . Stressful life events and coping styles in dysthymia and major depressivedisorder: variations associated with alleviation of symptomsfollowing pharmacotherapy Prog Neuro-Psychopharmacol BiolPsychiatry 1995; 19: 637–653

    Article  CAS  Google Scholar 

  189. McCullough JP, Kasnetz MD, Braith JA, Carr KF, Cones JH, Fielo J et al. A longitudinal study of an untreated sample of predominantly late onset characterological dysthymia J Nerv Ment Dis 1988; 176: 658–667

    Article  CAS  PubMed  Google Scholar 

  190. Benjaminsen S . Stressful life events preceding the onset of neurotic depression Psychol Med 1981; 11: 369–378

    Article  CAS  PubMed  Google Scholar 

  191. Monroe SM, Thase ME, Hersen M, Himmelhoch JM, Bellack AS . Life events and the endogenous-non-endogenous distinction in the treatment and posttreatment course of depression Comp Psychiatry 1985; 26: 175–186

    Article  CAS  Google Scholar 

  192. Dura JR, Stukenberg KW, Kiecolt-Glaser JK . Chronic stress and depressive disorder in older adults J Abn Psychol 1990; 99: 284–290

    Article  CAS  Google Scholar 

  193. Friedman RA . Social impairment in dysthymia Psychiat Ann 1993; 23: 632–637

    Article  Google Scholar 

  194. Walker V, Streiner DL, Novosel S, Rocchi A, Levine MAH, Dean DM . Health-related quality of life in patients with major depression who are treated with moclobemide J Clin Psychopharmacol 1995; 15: 60S–67S

    Article  CAS  PubMed  Google Scholar 

  195. Wells K, Stewart A, Hays R, Burnam M, Rogers W, Daniels M et al. The functioning and well-being of depressed patients: results from the Medical Outcome Study JAMA 1989; 262: 914–919

    Article  CAS  PubMed  Google Scholar 

  196. Cassano GB, Perugi G, Maremmani I, Akiskal HS . Social adjustment in dysthymia. In: Burton SW, Akiskal HS (eds) Dysthymic Disorders Gaskell: London 1990; pp78–85

    Google Scholar 

  197. De Lisio G, Maremmani I, Perugi G, Cassano GB, Deltito J, Akiskal HS . Impairment of work and leisure in depressed outpatients J Affect Disord 1986; 10: 79–84

    Article  CAS  PubMed  Google Scholar 

  198. Freeman HL . Historical and nosological aspects of dysthymia Acta Psychiat Scand 1994; 89: 7–11

    Article  Google Scholar 

  199. Leader JB, Klein DN . Social adjustment in dysthymia, double depression and episodic major depression J Affect Disord 1996; 37: 91–101

    Article  CAS  PubMed  Google Scholar 

  200. Markowitz JC, Friedman RA, Miller N, Spielman LA, Moran ME, Kocsis JH . Interpersonal improvement in chronically depressed patients treated with desipramine J Affect Disord 1996; 41: 59–62

    Article  CAS  PubMed  Google Scholar 

  201. Agosti V, Stewart JW, Quitkin FM . Life satisfaction and psychosocial functioniong in chronic depression: effect of acute treatment with antidepressants J Affect Disord 1991; 23: 35–41

    Article  CAS  PubMed  Google Scholar 

  202. Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ et al. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes Am J Psychiatry 1997; 154: 390–395

    Article  CAS  PubMed  Google Scholar 

  203. Klein DN, Lewinsohn PM, Seeley JR . Psychosocial characteristics of adolescents with a past history of dysthymic disorder: comparison with adolescents with past histories of major depression and non affective disorders, and never mentally ill controls J Affect Disord 1997; 42: 127–135

    Article  CAS  PubMed  Google Scholar 

  204. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline and imipramine J Clin Psychiatry 1998; 59: 608–619

    Article  CAS  PubMed  Google Scholar 

  205. Fawcett J . Antidepressants: partial response in chronic depression Br J Psychiatry Suppl 1994; 26: 37–41

    Article  Google Scholar 

  206. Paykel ES, Prusoff BA, Uhlenhuth EH . Scaling of life events Arch Gen Psychiatry 1971; 25: 340–347

    Article  CAS  PubMed  Google Scholar 

  207. Ramana R, Paykel ES, Cooper Z, Hayhurst H, Saxty M, Surtees PG . Remission and relapse in major depression: a two year prospective follow-up study Psychol Med 1995; 25: 1161–1170

    Article  CAS  PubMed  Google Scholar 

  208. Maes M . Evidence for an immune response in major depression: a review and hypothesis Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 11–38

    Article  CAS  PubMed  Google Scholar 

  209. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E . Interleukin-1 β: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993; 150: 1189–1193

    Article  CAS  PubMed  Google Scholar 

  210. Maes M, Bosmans E, Suy E, Vandervorst C, de Jonckheere C, Minner B et al. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1β and soluble interleukin-2 receptor production Acta Psychiatr Scand 1991; 84: 379–386

    Article  CAS  PubMed  Google Scholar 

  211. Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C et al. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining Psychol Med 1992; 22: 45–53

    Article  CAS  PubMed  Google Scholar 

  212. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression J Affect Disord 1995; 34: 301–309

    Article  CAS  PubMed  Google Scholar 

  213. Mullar N, Ackenheil M . Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders Prog Neuropsychopharm Biol Psychiatry 1998; 22: 1–33

    Article  Google Scholar 

  214. Nassberger L, Traskman-Bendz L . Increased soluble interleukin-2 receptor concentrations in suicide attempters Acta Psychiatr Scand 1993; 88: 48–52

    Article  CAS  PubMed  Google Scholar 

  215. Smith RS . The macrophage theory of depression Med Hypoth 1991; 35: 298–306

    Article  CAS  Google Scholar 

  216. Song C, Dinan T, Leonard BE . Changes in immunoglobulin, complement and acute phase protein levels in depressed patients and normal controls J Affect Disord 1994; 30: 283–288

    Article  CAS  PubMed  Google Scholar 

  217. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K . Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine Ann NY Acad Sci 1995; 762: 474–476

    Article  CAS  PubMed  Google Scholar 

  218. Anisman H, Ravindran AV, Griffiths J, Merali H . Interleukin-1 variations associated with dysthymia prior to and following antidepressant medication Biol Psychiatry (in press)

  219. Ravindran A, Griffiths J, Merali Z, Anisman H . Lymphocyte subsets in major depression and dysthymia: modification by antidepressant treatment Psychosomatic Med 1995; 57: 555–563

    Article  CAS  Google Scholar 

  220. Griffiths J, Ravindran AV, Merali Z, Anisman H . Immune and behavioral correlates of typical and atypical depression Soc Neurosci Abst 1996; 22: 1350

    Google Scholar 

  221. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJP et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome J Clin Endocrinol Metab 1991; 148: 337–344

    Google Scholar 

  222. Gold PW, Licinio J, Wong ML, Chrousos GP . Corticotropin releasing hormone in pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs Ann NY Acad Sci 1995; 771: 716–729

    Article  CAS  PubMed  Google Scholar 

  223. Dunn AJ . Interactions between the nervous system and the immune system: implications for psychopharmacology. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress Raven Press: New York 1995; pp719–731

    Google Scholar 

  224. Rivier C . Effect of peripheral and central cytokines on the hypothalamic-pituitary-adrenal axis of the rat Ann NY Acad Sci 1993; 697: 97–105

    Article  CAS  PubMed  Google Scholar 

  225. Maes M . Major depression and activation of the inflammatory response system Adv Exp Med Biol 1999; 461: 25–46

    Article  CAS  PubMed  Google Scholar 

  226. Capuron L, Ravaud A, Radat F, Dantzer R, Goodall G . Affects of interleukin-2 and alpha-interferon cytokine immunotherapy on the mood and cognitive performance of cancer patients Neuroimmunomodulation 1998; 5: 9

    Article  Google Scholar 

  227. Caraceni A, Martini C, Belli F, Mascheroni L, Rivoltini L, Arienti F et al. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration Eur J Cancer 1992; 29A: 1266–1269

    Google Scholar 

  228. Denicoff KD, Rubinow DR, Papa MZ, Simpson L, Seipp LA, Lotze MT et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells Ann Int Med 1987; 107: 293–300

    Article  CAS  PubMed  Google Scholar 

  229. Meyers CA, Valentine AD . Neurological and psychiatric adverse effects of immunological therapy CNS Drugs 1995; 3: 56–68

    Article  Google Scholar 

  230. Meyers CA . Mood and cognitive disorders in cancer patients receiving cytokine therapy Adv Exp Med Biol 1999; 461: 75–81

    Article  CAS  PubMed  Google Scholar 

  231. Post RM, Weiss SRB . The neurobiology of treatment-resistant mood disorders. In: Bloom FE, Kupfer DJ (eds) Psychopharmaícology: The Fourth Generation of Progress Raven Press: New York 1995; pp1155–1170

    Google Scholar 

  232. Perris H . Life events and depression. Part 2. Results in diagnostic subgroups, and in relation to the recurrence of depression J Affect Disord 1984; 7: 25–36

    Article  CAS  PubMed  Google Scholar 

  233. Thase ME, Sullivan LR . Relapse and recurrence of depression: a practical approach for prevention CNS Drugs 1995; 4: 261–277

    Article  CAS  Google Scholar 

  234. Post RM . Transduction of psychosocial stress into the neurobiology of recurrent affective disorder Am J Psychiatry 1992; 149: 999–1010

    Article  CAS  PubMed  Google Scholar 

  235. Anisman H, Merali Z . Anhedonic and anxiogenic effects of cytokine exposure Adv Exp Med Biol 1999; 461: 199–233

    Article  CAS  PubMed  Google Scholar 

  236. De Kloet ER, Reul JMH . Feedback action and tonic influence of corticosteroids on brain function: a concept arising from heterogeneity of brain receptor systems Psychoneuroendocrinology 1987; 12: 83–105

    Article  CAS  PubMed  Google Scholar 

  237. Dinan TG . Glucocorticoids and the genesis of depressive illness: a psychobiological model Br J Psychiatry 1994; 164: 365–371

    Article  CAS  PubMed  Google Scholar 

  238. Merali Z, McIntosh J, Kent P, Michaud D, Anisman H . Aversive as well as appetitive events evoke the release of corticotropin releasing hormone and bombesin-like peptides at the central nucleus of the amygdala J Neurosci 1998; 18: 4758–4766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  239. Kalivas PW, Stewart J . Dopamine transmission in the initiation and expression of drug-and stress-induced sensitization of motor activity Brain Res Rev 1991; 16: 223–244

    Article  CAS  PubMed  Google Scholar 

  240. Nemeroff CB . The corticotropin-releasing factor (CRF) hypothsesis of depression: new findings and new directions Mol Psychiatry 1996; 1: 336–342

    CAS  PubMed  Google Scholar 

  241. Levitan RD, Kaplan AS, Brown GM, Joffe RT, Levitt AJ, Vaccarino FJ et al. Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression Biol Psychiatry 1997; 41: 366–368

    Article  CAS  PubMed  Google Scholar 

  242. Catalan R, Gallart JM, Castellanos JM, Galard R . Plasma corticotropin-releasing factor in depressive disorders Biol Psychiatry 1998; 44: 15–20

    Article  CAS  PubMed  Google Scholar 

  243. Bartanusz V, Jezova D, Bertini LT, Tilders FJ, Aubry JM, Kiss JZ . Stress-induced increase in vasopressin and corticotropin-releasing factor expression in hypophysiotrophic paraventricular neurons Endocrinology 1993; 132: 895–902

    Article  CAS  PubMed  Google Scholar 

  244. Schmidt ED, Binnbekade R, Janszen AWJW, Tilders FJH . Short stressor induced long-lasting increases of vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult rats J Neuroendocrinol 1996; 8: 703–712

    Article  CAS  PubMed  Google Scholar 

  245. Schmidt E, Janszen AWJW, Wouterlood FG, Tilders FJH . Interleukin-1 induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH) neurons and hyperresponsiveness of the hypothalamic-pituitary-adrenal axis J Neurosci 1995; 15: 7417–7426

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  246. Tilders FJH, Schmidt ED, De Goeij DCE . Phenotypic plasticity of CRF neurons during stress Ann NY Acad Sci 1993; 697: 39–52

    Article  CAS  PubMed  Google Scholar 

  247. Tilders FJH, Schmidt ED . Interleukin-1-induced plasticity of hypothalamic CRH neurons and long-term stress hyperresponsiveness Ann NY Acad Sci 1998; 840: 65–73

    Article  CAS  PubMed  Google Scholar 

  248. Gold PW, Chrousos GP, Kellner C, Post RM, Roy A, Augerinas P et al. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor Am J Psychiatry 1984; 141: 619–627

    Article  CAS  PubMed  Google Scholar 

  249. Banki CM, Karmacsi L, Bissette G, Nemeroff CB . CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse Eur Neuropsychopharmacol 1992; 2: 107–113

    Article  CAS  PubMed  Google Scholar 

  250. Blalock JE . The syntax of immune-neuroendocrine communication Immunol Today 1994; 15: 504–511

    Article  CAS  PubMed  Google Scholar 

  251. Dunn AJ . Interleukin-1 as a stimulator of hormone secretion Prog NeuroEndocrinImmunol 1990; 3: 26–34

    Google Scholar 

  252. Herman JP, Cullinan WE . Neurocircuitry of stress: central control of hypothalamo-pituitary-adrenocortical axis Trends Neurosci 1997; 20: 78–84

    Article  CAS  PubMed  Google Scholar 

  253. Crnic LS . Behavioral consequences of viral infection. In: Ader R, Felten DL, Cohen N (eds) Psychoneuroimmunology Academic Press: San Diego 1991; 749–770

    Chapter  Google Scholar 

  254. Lacosta S, Merali Z, Anisman H . Influence of interleukin-1 on exploratory behaviors, plasma ACTH and cortisol, and central biogenic amines in mice Psychopharmacology 1998; 137: 351–361

    Article  CAS  PubMed  Google Scholar 

  255. Linthorst ACE, Flachskamm C, Muller-Preuss P, Holsboer F, Reul JMHM . Effect of bacterial endotoxin and interleukin-1β on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study J Neurosci 1995; 15: 2920–2934

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  256. Song C, Merali Z, Anisman H . Systemically administered IL-1, IL-2 and IL-6 and mild stress influence in vivo monoamine variations in the nucleus accumbens Neuroscience 1998; 88: 823–836

    Article  Google Scholar 

  257. Kent S, Bluthe RM, Kelley KW, Dantzer R . Sickness behavior as a new target for drug development Trends Pharmacol Sci 1992; 13: 24–28

    Article  CAS  PubMed  Google Scholar 

  258. Anisman H, Zaharia MD, Meaney MJ, Merali Z . Proactive hormonal, neurochemical and behavioral effects of early life stimulation; genetic differences Int J Dev Neurosci 1998; 16: 149–164

    Article  CAS  PubMed  Google Scholar 

  259. Meaney MJ, Diorio J, Francis D, Widdowson J, LaPlante P, Caldji C et al. Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress Dev Neuroscience 1996; 18: 49–72

    Article  CAS  Google Scholar 

  260. Akiskal HS, Cassano GB . Dysthymia and the Spectrum of Chronic Depressions Guilford Press: New York 1997

    Google Scholar 

Download references

Acknowledgements

This work was supported by the Medical Research Council of Canada. HA is an Ontario Mental Health Foundation Senior Research Fellow.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Ottawa, Ottawa, Canada

    J Griffiths, A V Ravindran, Z Merali & H Anisman

  2. Institute of Cellular and Molecular Medicine, Ottawa, Canada

    Z Merali

  3. Institute of Neuroscience, Carleton University, Ottawa, Canada

    H Anisman

Authors
  1. J Griffiths
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A V Ravindran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z Merali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Anisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Anisman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Griffiths, J., Ravindran, A., Merali, Z. et al. Dysthymia: a review of pharmacological and behavioral factors. Mol Psychiatry 5, 242–261 (2000). https://doi.org/10.1038/sj.mp.4000697

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4000697

Keywords

This article is cited by

Search

Advanced search

Quick links